MX9804119A - Analogos de antraciclina citotoxica dirigidos. - Google Patents
Analogos de antraciclina citotoxica dirigidos.Info
- Publication number
- MX9804119A MX9804119A MX9804119A MX9804119A MX9804119A MX 9804119 A MX9804119 A MX 9804119A MX 9804119 A MX9804119 A MX 9804119A MX 9804119 A MX9804119 A MX 9804119A MX 9804119 A MX9804119 A MX 9804119A
- Authority
- MX
- Mexico
- Prior art keywords
- deamino
- doxorubicin
- dox
- analogs
- moiety
- Prior art date
Links
- 229940045799 anthracyclines and related substance Drugs 0.000 title abstract 2
- 231100000433 cytotoxic Toxicity 0.000 title 1
- 230000001472 cytotoxic effect Effects 0.000 title 1
- 229960004679 doxorubicin Drugs 0.000 abstract 9
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 102000005157 Somatostatin Human genes 0.000 abstract 2
- 108010056088 Somatostatin Proteins 0.000 abstract 2
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 abstract 2
- 239000000813 peptide hormone Substances 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 229920006395 saturated elastomer Chemical group 0.000 abstract 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 abstract 2
- 229960000553 somatostatin Drugs 0.000 abstract 2
- 150000000565 5-membered heterocyclic compounds Chemical class 0.000 abstract 1
- 150000000644 6-membered heterocyclic compounds Chemical class 0.000 abstract 1
- 108010051479 Bombesin Proteins 0.000 abstract 1
- 102000013585 Bombesin Human genes 0.000 abstract 1
- 101000904177 Clupea pallasii Gonadoliberin-1 Proteins 0.000 abstract 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 abstract 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 abstract 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 abstract 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- KAKZBPTYRLMSJV-UHFFFAOYSA-N butadiene group Chemical group C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- WPJRFCZKZXBUNI-HCWXCVPCSA-N daunosamine Chemical compound C[C@H](O)[C@@H](O)[C@@H](N)CC=O WPJRFCZKZXBUNI-HCWXCVPCSA-N 0.000 abstract 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 abstract 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/562,652 US5843903A (en) | 1995-11-27 | 1995-11-27 | Targeted cytotoxic anthracycline analogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX9804119A true MX9804119A (es) | 1998-09-30 |
Family
ID=24247176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9804119A MX9804119A (es) | 1995-11-27 | 1998-05-25 | Analogos de antraciclina citotoxica dirigidos. |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US5843903A (https=) |
| EP (2) | EP0863917B1 (https=) |
| JP (2) | JP3987575B2 (https=) |
| KR (2) | KR100467899B1 (https=) |
| CN (2) | CN1166597C (https=) |
| AT (2) | ATE401305T1 (https=) |
| AU (1) | AU709539B2 (https=) |
| BR (1) | BR9611647B1 (https=) |
| CA (2) | CA2238574C (https=) |
| CZ (1) | CZ297297B6 (https=) |
| DE (2) | DE69630233T2 (https=) |
| DK (2) | DK1384710T3 (https=) |
| EA (1) | EA001372B1 (https=) |
| ES (2) | ES2310222T3 (https=) |
| HK (1) | HK1052920B (https=) |
| HU (1) | HU229870B1 (https=) |
| IL (3) | IL119691A (https=) |
| IS (2) | IS2178B (https=) |
| MX (1) | MX9804119A (https=) |
| NO (2) | NO324035B1 (https=) |
| NZ (1) | NZ322054A (https=) |
| PL (3) | PL191781B1 (https=) |
| PT (2) | PT863917E (https=) |
| SK (2) | SK284672B6 (https=) |
| UA (1) | UA67722C2 (https=) |
| WO (1) | WO1997019954A1 (https=) |
| ZA (1) | ZA969709B (https=) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6576239B1 (en) | 1996-09-10 | 2003-06-10 | The Burnham Institute | Angiogenic homing molecules and conjugates derived therefrom |
| US6180084B1 (en) | 1998-08-25 | 2001-01-30 | The Burnham Institute | NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same |
| GB9814527D0 (en) | 1998-07-03 | 1998-09-02 | Cyclacel Ltd | Delivery system |
| AU766489B2 (en) | 1998-11-13 | 2003-10-16 | Cyclacel Limited | Transport vectors |
| FR2786397B1 (fr) * | 1998-11-30 | 2003-01-10 | Synt Em | Vecteurs peptidiques de substances a travers la barriere hematoencephalique pour etre utilises dans le diagnostic ou la therapie d'une affection du snc |
| FR2786398B1 (fr) * | 1998-11-30 | 2002-12-27 | Synt Em | Composition pharmaceutique anti-cancereuse et anti-chimioresistance comprenant un agent anticancereux et au moins un peptide |
| US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| US6528481B1 (en) | 1999-02-16 | 2003-03-04 | The Burnam Institute | NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods |
| US6380161B1 (en) | 1999-06-21 | 2002-04-30 | Inkine Pharmaceutical Company, Inc. | Compositions for treating chemotherapy-resistant tumor cells and targeted chemotherapy compositions |
| CA2388844A1 (en) * | 1999-11-12 | 2001-05-25 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors |
| AU767394C (en) | 1999-12-29 | 2005-04-21 | Immunogen, Inc. | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
| AU4267700A (en) * | 2000-01-13 | 2001-07-19 | Academia Sinica | Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells |
| NZ522200A (en) * | 2000-04-26 | 2004-07-30 | Biosynthema Inc | RGD (ARG-GLY-ASP) coupled to (neuro)peptides |
| US7452964B2 (en) | 2001-09-07 | 2008-11-18 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides against placenta and adipose tissues |
| US7420030B2 (en) | 2000-09-08 | 2008-09-02 | The Board Of Regents Of The University Of Texas System | Aminopeptidase A (APA) targeting peptides for the treatment of cancer |
| US20040170955A1 (en) | 2000-09-08 | 2004-09-02 | Wadih Arap | Human and mouse targeting peptides identified by phage display |
| KR100420007B1 (ko) * | 2001-04-25 | 2004-03-02 | 노영쇠 | 안트라사이클린 유도체 및 이를 포함하는 항암제 |
| CN1589151A (zh) | 2001-09-21 | 2005-03-02 | 图兰恩教育基金管理人 | 诊断或治疗性促生长素抑制素或铃蟾肽类似物的连接物及其用途 |
| EP1531846A4 (en) * | 2002-02-27 | 2006-04-19 | Us Gov Health & Human Serv | Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use |
| US7771727B2 (en) | 2002-03-01 | 2010-08-10 | The Administrators Of The Tulane Educational Fund | Conjugates of therapeutic or cytotoxic agents and biologically active peptides |
| US7544767B2 (en) | 2002-04-05 | 2009-06-09 | Burnham Institute For Medical Research | HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells |
| EP1506786B1 (en) * | 2002-05-21 | 2016-11-23 | Daiichi Sankyo Company, Limited | Medicinal compositions containing ghrelin |
| US8313760B2 (en) | 2002-05-24 | 2012-11-20 | Angiotech International Ag | Compositions and methods for coating medical implants |
| CN101134119A (zh) | 2002-05-24 | 2008-03-05 | 血管技术国际股份公司 | 用于涂覆医用植入物的组合物和方法 |
| EP1542739B1 (en) | 2002-09-26 | 2008-12-10 | Angiotech International Ag | Perivascular wraps |
| AU2003300076C1 (en) | 2002-12-30 | 2010-03-04 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
| US20040202666A1 (en) * | 2003-01-24 | 2004-10-14 | Immunomedics, Inc. | Anti-cancer anthracycline drug-antibody conjugates |
| US20050043215A1 (en) | 2003-02-19 | 2005-02-24 | Tamara Minko | Complex drug delivery composition and method for treating cancer |
| AU2007221964B2 (en) * | 2003-04-22 | 2008-12-11 | Ipsen Pharma S.A.S. | Peptide vectors |
| CN101791409A (zh) * | 2003-04-22 | 2010-08-04 | 研究及应用科学协会股份有限公司 | 肽载体 |
| US7097993B2 (en) | 2003-06-25 | 2006-08-29 | Wisconsin Alumni Research Foundation | Method for identifying an agent that modulates type 1 phosphatidylinositol phosphate kinase isoform β661 activity |
| WO2005086951A2 (en) * | 2004-03-10 | 2005-09-22 | Threshold Pharmaceuticals, Inc. | Hypoxia-activated anti-cancer agents |
| US20070060534A1 (en) * | 2005-06-30 | 2007-03-15 | Threshold Pharmaceuticals, Inc. | Anthracycline analogs |
| JP5340155B2 (ja) * | 2006-09-06 | 2013-11-13 | エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 細胞結合分子を有するジソラゾールのコンジュゲート及びそれらの誘導体、新規ジソラゾール誘導体、それらの製法ならびに使用 |
| EP1900742A1 (en) | 2006-09-07 | 2008-03-19 | AEterna Zentaris GmbH | Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof |
| US20100087370A1 (en) * | 2007-02-14 | 2010-04-08 | The General Hospital Corporation | Modulation of nitric oxide signaling to normalize tumor vasculature |
| RU2377247C2 (ru) * | 2007-12-27 | 2009-12-27 | Федеральное государственное образовательное учреждение высшего профессионального образования Санкт-Петербургский государственный университет | Молекулярный конъюгат на основе синтетических аналогов люлиберина и его применение в качестве средства доставки днк в клетки гормон-чувствительных опухолей (варианты) |
| EP2240495B1 (en) | 2008-02-01 | 2015-07-15 | Genentech, Inc. | Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods |
| CA2721140C (en) * | 2008-04-11 | 2016-02-09 | Tianjin Hemay Bio-Tech Co. Ltd. | Tetracyclic anthraquinone antibiotic derivatives with high activity, process for preparing the same and use thereof |
| KR101328315B1 (ko) * | 2008-04-11 | 2013-11-11 | 티안진 헤메이 바이오-텍 컴퍼니 리미티드 | 고활성의 안트라사이클린 항생물질 유도체, 이의 제조방법 및 사용 |
| AU2009270988A1 (en) | 2008-07-15 | 2010-01-21 | Genentech, Inc. | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds |
| JP5584236B2 (ja) | 2009-02-20 | 2014-09-03 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ | 神経ペプチドｙ受容体結合化合物を有する細胞毒性コンジュゲート |
| CN102050856B (zh) * | 2009-11-03 | 2014-04-30 | 天津和美生物技术有限公司 | 具有高活性的表阿霉素的衍生物及其制备和应用 |
| KR101897307B1 (ko) | 2010-12-02 | 2018-09-10 | 네르비아노 메디칼 사이언시스 에스.알.엘. | 모르폴리닐 안트라사이클린 유도체의 제조 방법 |
| CN105198966B (zh) * | 2014-06-26 | 2019-06-21 | 中国人民解放军军事医学科学院毒物药物研究所 | GnRH类似物-细胞毒分子缀合物、其制备方法及用途 |
| MX379365B (es) | 2014-06-30 | 2025-03-11 | Tarveda Therapeutics Inc | Conjugados y partículas direccionados y formulaciones de estos. |
| EP3045540A1 (en) | 2015-01-19 | 2016-07-20 | Æterna Zentaris GmbH | Enzymatic process for the regioselective manufacturing of N-Fmoc-doxorubicin-14-O-dicarboxylic acid mono esters |
| US11160871B2 (en) | 2015-10-28 | 2021-11-02 | Tarveda Therapeutics, Inc. | SSTR-targeted conjugates and particles and formulations thereof |
| US10450340B2 (en) | 2017-02-16 | 2019-10-22 | Monopar Therapeutics Inc. | 3′-deamino-3′-(2″-pyrroline-1″-yl)-5-imino-13-deoxyanthracyclines and methods of preparation |
| WO2021068051A1 (en) * | 2018-11-13 | 2021-04-15 | Provincial Health Services Authority | Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders |
| AU2023239751A1 (en) | 2022-03-25 | 2024-09-05 | Provincial Health Services Authority | Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3725350A (en) * | 1972-04-26 | 1973-04-03 | Commercial Soluents Corp | Polymeric substances comprising the reaction product of melamine, aldehyde and oxazolidines |
| US4299822A (en) * | 1980-06-09 | 1981-11-10 | Sidney Farber Cancer Institute, Inc. | N-Trifluoroacetyladriamycin-14-O-hemiglutarate and -hemiadipate and therapeutic compositions containing same |
| US4464529A (en) * | 1982-07-20 | 1984-08-07 | Sri International | Analogues of morpholinyl daunorubicin and morpholinyl doxorubicin |
| IL106992A (en) * | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Acylhydrazone derivatives of anthracycline and methods for their preparation |
| US5217955A (en) * | 1989-09-15 | 1993-06-08 | Biomeasure, Inc. | Treatment of cancer with peptide analog of bombesin, grp, litorin or neuromedin |
| DK0434960T3 (da) * | 1989-12-19 | 1996-10-14 | Pharmacia Spa | Chirale 1,5-diiod-2-methoxy- eller benzyloxymellemprodukter |
| US5304687A (en) * | 1989-12-19 | 1994-04-19 | Farmitalia Carlo Erba S.R.L. | Morpholinyl derivatives of doxorubicin and process for their preparation |
| DK0450461T3 (da) * | 1990-04-06 | 1995-10-23 | Univ Tulane | LHRH-analoger |
| DK0450480T3 (da) * | 1990-04-06 | 1995-08-14 | Univ Tulane | Somatostatinaloger |
| JP3169425B2 (ja) * | 1992-03-27 | 2001-05-28 | 三共株式会社 | アジドペンタンサイクリトール |
| US6214345B1 (en) * | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
-
1995
- 1995-11-27 US US08/562,652 patent/US5843903A/en not_active Expired - Lifetime
-
1996
- 1996-11-14 AT AT03010988T patent/ATE401305T1/de active
- 1996-11-14 CN CNB021439192A patent/CN1166597C/zh not_active Expired - Lifetime
- 1996-11-14 CA CA002238574A patent/CA2238574C/en not_active Expired - Lifetime
- 1996-11-14 PL PL358737A patent/PL191781B1/pl unknown
- 1996-11-14 SK SK341-2004A patent/SK284672B6/sk not_active IP Right Cessation
- 1996-11-14 ES ES03010988T patent/ES2310222T3/es not_active Expired - Lifetime
- 1996-11-14 DK DK03010988T patent/DK1384710T3/da active
- 1996-11-14 NZ NZ322054A patent/NZ322054A/en not_active IP Right Cessation
- 1996-11-14 CZ CZ0135798A patent/CZ297297B6/cs not_active IP Right Cessation
- 1996-11-14 BR BRPI9611647-1A patent/BR9611647B1/pt not_active IP Right Cessation
- 1996-11-14 WO PCT/EP1996/005029 patent/WO1997019954A1/en not_active Ceased
- 1996-11-14 HU HU9903771A patent/HU229870B1/hu unknown
- 1996-11-14 KR KR10-2004-7004548A patent/KR100467899B1/ko not_active Expired - Lifetime
- 1996-11-14 CA CA002471775A patent/CA2471775C/en not_active Expired - Lifetime
- 1996-11-14 AT AT96938216T patent/ATE251179T1/de active
- 1996-11-14 EA EA199800492A patent/EA001372B1/ru not_active IP Right Cessation
- 1996-11-14 UA UA98063318A patent/UA67722C2/uk unknown
- 1996-11-14 AU AU75722/96A patent/AU709539B2/en not_active Expired
- 1996-11-14 PT PT96938216T patent/PT863917E/pt unknown
- 1996-11-14 EP EP96938216A patent/EP0863917B1/en not_active Expired - Lifetime
- 1996-11-14 DK DK96938216T patent/DK0863917T3/da active
- 1996-11-14 PT PT03010988T patent/PT1384710E/pt unknown
- 1996-11-14 PL PL96358646A patent/PL188786B1/pl unknown
- 1996-11-14 JP JP52012397A patent/JP3987575B2/ja not_active Expired - Lifetime
- 1996-11-14 EP EP03010988A patent/EP1384710B1/en not_active Expired - Lifetime
- 1996-11-14 PL PL96326865A patent/PL187230B1/pl unknown
- 1996-11-14 DE DE69630233T patent/DE69630233T2/de not_active Expired - Lifetime
- 1996-11-14 SK SK628-98A patent/SK284392B6/sk unknown
- 1996-11-14 DE DE69637604T patent/DE69637604D1/de not_active Expired - Lifetime
- 1996-11-14 CN CNB961986050A patent/CN1137136C/zh not_active Expired - Lifetime
- 1996-11-14 ES ES96938216T patent/ES2205067T3/es not_active Expired - Lifetime
- 1996-11-14 KR KR10-1998-0703948A patent/KR100445754B1/ko not_active Expired - Lifetime
- 1996-11-20 ZA ZA9609709A patent/ZA969709B/xx unknown
- 1996-11-26 IL IL11969196A patent/IL119691A/en not_active IP Right Cessation
- 1996-11-26 IL IL13468596A patent/IL134685A/en not_active IP Right Cessation
-
1998
- 1998-05-05 IS IS4734A patent/IS2178B/is unknown
- 1998-05-15 NO NO19982252A patent/NO324035B1/no not_active IP Right Cessation
- 1998-05-25 MX MX9804119A patent/MX9804119A/es unknown
- 1998-07-15 US US09/116,125 patent/US6184374B1/en not_active Expired - Lifetime
-
2000
- 2000-02-23 IL IL13468500A patent/IL134685A0/xx unknown
-
2003
- 2003-07-09 HK HK03104934.8A patent/HK1052920B/zh not_active IP Right Cessation
-
2005
- 2005-03-01 NO NO20051111A patent/NO20051111L/no not_active Application Discontinuation
-
2006
- 2006-11-09 IS IS8567A patent/IS2634B/is unknown
- 2006-11-15 JP JP2006309698A patent/JP4778405B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX9804119A (es) | Analogos de antraciclina citotoxica dirigidos. | |
| KR100274373B1 (en) | Methylthiomethyl ethers of taxane derivatives | |
| IL110660A0 (en) | Phosphonooxymethyl ethers of taxane derivatives | |
| HU9302762D0 (en) | N-sulfonyl-2-oxoindole derivatives being effective on vasopressin and/or oxitocin receptors | |
| IL159773A0 (en) | Taxol enhancer compounds | |
| IL103301A0 (en) | Pyrimidine nucleoside derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same | |
| KR960701661A (ko) | AIDS치료용 약제학적 배합물중의 HIV프로테아제 억제제(HIV protease inhibitors in pharmaceutical combinations for the treament of AIDS) | |
| IL106672A0 (en) | 9-((substituted glycyl)amino))-6-demethyl-6-deoxytetracyclines | |
| DK0909184T3 (da) | Målrettet lægemiddelindgivelse ved anvendelse af sulfonamidderivater | |
| YU41199A (sh) | Hinoksalindioni | |
| CA2155018A1 (en) | C7 taxane derivatives and pharmaceutical compositions containing them | |
| JPS55120592A (en) | Solubilization of organic or inorganic salt into organic solvent | |
| CA2275451A1 (en) | Radioactive technetium and rhenium nitride heterocomplexes | |
| CA2411172C (en) | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase i and ii inhibitors | |
| ZA941198B (en) | Highly concentrated TCF pharmaceutical preparations | |
| US5908919A (en) | Urethane mediated, GST specific molecular release systems | |
| CA2136438A1 (en) | Anthracycline conjugates, their preparation and their use as antitumor agents | |
| GB2008096A (en) | (2-Oxo-pyrrolidine-1)- and (2-oxo- piperidine-1) carboxylic acid hydrazides, process for the manufacture thereof, and pharmaceutical preparations containing them | |
| GR862436B (en) | Method for preparing conjugate compounds of vinblastine and its derivatives and pharmaceutical compositions containing the conjucate compounds | |
| CA2022538A1 (fr) | Derives n-(vincristinoyl-23) et n-(noranhydro-5' vinblastinoyl-23) d'acide amino-1 methylphosphonique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| HU906945D0 (en) | Process for producing (1r,r2)-2-(3-pyridyl)-tetrahydrothiopyrane-2-carbothioamide-1-oxides and pharmaceutical preparatives containing these compounds | |
| HU9500585D0 (en) | Hepatotropic conjugates of antiviral drugs, carriers thereof and pharmaceutical compositions containing them | |
| CA2021942A1 (en) | Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent | |
| WO1999053908A3 (en) | Pro-drug conjugates for the treatment of stroke and other ischaemic conditions |